)

Verastem (VSTM) investor relations material
Verastem H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key product launches and commercial progress
Achieved accelerated FDA approval for avutometinib plus defactinib in low-grade serous ovarian cancer, with a 44% response rate in pivotal study and over $2 million net sales in the first six weeks post-launch.
Strong momentum continues into the first full quarter, with positive feedback from physicians and patients.
No immediate plans for Canada; regulatory discussions ongoing in Europe and Japan, with a bridging study in Japan nearing full accrual and potential conditional approval targeted for 2027.
Clinical development and pipeline updates
Confirmatory Phase 3 trial in ovarian cancer is nearly fully accrued, with a pre-planned interim analysis expected later this year to assess sample size and study direction.
Expansion of avutometinib plus defactinib into other indications, including G12C non-small cell lung cancer (in partnership with Amgen) and frontline metastatic pancreatic cancer, with 83% response rate in the latter.
VS-7375, a dual on-off KRAS G12D inhibitor, shows promising data from partner GenFleet Therapeutics: 52% response rate in pancreatic cancer and 69% in lung cancer at recommended dose.
U.S. Phase 1 for VS-7375 is progressing rapidly, with safety data expected later this year and initial efficacy data in the first half of next year; combination regimens to begin soon.
Financial position and strategic outlook
Cash position over $160 million, with an additional $50 million expected from in-the-money warrants, providing runway into the second half of 2026.
LGSOC business could become self-funding by 2026; future funding for G12D program may come from sales, partnerships, or equity raises, with partnerships preferred over dilution.
Additional line of credit available but not yet drawn; financial strategy will adapt to data, sales, and macroeconomic conditions.
Next Verastem earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage